Biochemistry and Immunology of Poly(ethylene glycol)-Modified Adenosine Deaminase (PEG-ADA)

摘要

Poly(ethylene glycol) -modified bovine adenosine deaminase (PEG-ADA) was the first PEGylated protein to undergo clinical trials. It has been effective in correcting the toxic biochemical effects of ADA substrates, and in treating the fatal immune deficiency disease caused by ADA deficiency. The experience gained from monitoring PEG-ADA therapy over the past decade provides unique insight into the immunological response to chronic treatment with a PEGylated enzyme.